322.80
-0.20
(-0.06%)
As of 8:05:02 AM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. William J. Sibold | CEO, President & Director | 1.6M | -- | 1966 |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 889.91k | -- | 1952 |
| Ms. Carole Huntsman | Chief Commercial Officer | 90.13k | -- | 1965 |
| Ms. Mardi C. Dier | CFO & Senior VP | -- | -- | 1964 |
| Mr. Mark Underwood | Senior Vice President of Business Planning & Operations | -- | -- | -- |
| Mr. Ronald Filippo | Chief Information Officer | -- | -- | -- |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | -- | -- | -- |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel | -- | -- | -- |
| Mr. Clint Wallace | Chief Human Resources Officer | -- | -- | -- |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | -- | -- | -- |
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 376
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Corporate Governance
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
February 26, 2025 at 1:30 PM UTC - March 3, 2025 at 1:30 PM UTC
Madrigal Pharmaceuticals, Inc. Earnings Date
Recent Events
Recent Events Information Not Available